84. Sarcoidosis Clinical trials / Disease details


Clinical trials : 149 Drugs : 227 - (DrugBank : 81) / Drug target genes : 82 - Drug target pathways : 167

  
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02523092
(ClinicalTrials.gov)
October 202010/8/2015Use of CXCL9 as a Biomarker of Acthar EfficacyUse of CXCL9 as a Biomarker of Acthar EfficacySarcoidosisDrug: Acthar gelUniversity of California, San FranciscoMallinckrodtNot yet recruiting18 Years65 YearsAll14Phase 4United States
2NCT02920710
(ClinicalTrials.gov)
February 1, 201929/9/2016ACTHAR Therapy for Central Nervous System SarcoidosisACTHAR Therapy for Central Nervous System SarcoidosisSarcoidosisDrug: Repository Corticotropin InjectionThe Cleveland ClinicMallinckrodtWithdrawnN/AN/AAll0Phase 4United States
3NCT03320070
(ClinicalTrials.gov)
February 21, 201820/10/2017Acthar Gel in Participants With Pulmonary SarcoidosisA Phase 4, Multicenter, Randomized, Double Blind, Placebo Controlled Pilot Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Pulmonary SarcoidosisSarcoidosis, PulmonaryDrug: Acthar Gel;Drug: PlaceboMallinckrodtNULLCompleted18 Years90 YearsAll55Phase 4United States
4NCT02725177
(ClinicalTrials.gov)
July 201611/3/2016Ocular Sarcoidosis Open Label Trial of ACTHAR GelOcular Sarcoidosis Open Label Trial of ACTHAR GelOcular Sarcoidosis;Panuveitis;Anterior UveitisDrug: Repository Corticotropin Injection;Drug: Repository Corticotropin Injection -Treatment ExtensionThe Cleveland ClinicMallinckrodtRecruiting18 Years99 YearsAll20N/AUnited States
5NCT02298491
(ClinicalTrials.gov)
May 201614/11/2014CNS Sarcoidosis and Acthar GelClinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar GelCNS SarcoidosisDrug: H.P. Acthar GelUniversity of Maryland, BaltimoreMallinckrodtCompletedN/AN/AAll4Phase 4United States
6NCT02348905
(ClinicalTrials.gov)
March 201520/6/2014ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label TrialACTHAR Gel for Cutaneous Sarcoidosis: An Open Label TrialSarcoidosis;Cutaneous SarcoidosisDrug: ACTHAR Gel 40 units twice weekly;Drug: ACTHAR Gel 80 units twice weekly.Albany Medical CollegeNULLNot yet recruiting18 YearsN/ABoth10Phase 2/Phase 3United States
7NCT02155803
(ClinicalTrials.gov)
February 201530/5/2014ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot StudyACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot StudySarcoidosis;Hypercalcemia Due to SarcoidosisDrug: ACTHAR Gel (adrenocorticotropic hormone)Albany Medical CollegeNULLNot yet recruiting18 YearsN/ABoth10Phase 2/Phase 3United States
8NCT02188017
(ClinicalTrials.gov)
June 201424/4/2014Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)ACTHAR Gel for Chronic Pulmonary Sarcoidosis (ACPS)Sarcoidosis;Pulmonary SarcoidosisDrug: Acthar gelUniversity of CincinnatiMallinckrodtRecruiting18 Years90 YearsBoth20Phase 4United States